Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment

R Panaccione, J Colombel, R Enns, B Feagan, S Hanauer, Ian Lawrance, P Rutgeerts, W Sandborn, S Schreiber, S Targan, S Van Deventer

    Research output: Chapter in Book/Conference paperConference paper

    Original languageEnglish
    Title of host publicationINFLAMMATORY BOWEL DISEASES
    PagesS10-S10
    Volume14
    Publication statusPublished - 2008
    EventNatalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment -
    Duration: 1 Jan 2008 → …

    Conference

    ConferenceNatalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment
    Period1/01/08 → …

    Cite this

    Panaccione, R., Colombel, J., Enns, R., Feagan, B., Hanauer, S., Lawrance, I., Rutgeerts, P., Sandborn, W., Schreiber, S., Targan, S., & Van Deventer, S. (2008). Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment. In INFLAMMATORY BOWEL DISEASES (Vol. 14, pp. S10-S10)